Sarah Souffrant
Family · Edinburg, TXNPI 1134746233
Payments from drug & device makers
Across 111 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$538
- AbbVie$245
- Lilly USA, LLC$197
- Lundbeck LLC$191
- Livanova USA, Inc.$150
- Teva Pharmaceuticals USA, Inc.$102
- plus $728 from 16 others
What the payments were for
- Food & beverage$2,151100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 25 | $538 |
| AbbVie | 23 | $245 |
| Lilly USA, LLC | 6 | $197 |
| Lundbeck LLC | 15 | $191 |
| Livanova USA, Inc. | 6 | $150 |
| Teva Pharmaceuticals USA, Inc. | 4 | $102 |
| AstraZeneca | 3 | $94 |
| Jazz Pharmaceuticals Inc. | 5 | $93 |
| Acadia Pharmaceuticals Inc | 4 | $79 |
| Pfizer | 3 | $79 |
| Argenx US, Inc. | 3 | $58 |
| Johnson & Johnson | 2 | $51 |
| SK Life Science, Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $27 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| GSK | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$112
How this compares
$2,151 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 45 | $377 |
| Omeprazole | 16 | $376 |
| Tamsulosin Hcl | 17 | $271 |
| Lisinopril | 46 | $247 |
| Amlodipine Besylate | 22 | $220 |
| Losartan Potassium | 22 | $212 |
| Rosuvastatin Calcium | 22 | $209 |
| Metformin Hcl | 27 | $185 |
| Famotidine | 11 | $158 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $135 |
| Glipizide | 15 | $96 |
| Metoprolol Tartrate | 12 | $63 |
| Pantoprazole Sodium | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Other family in Edinburg
- Mayra CantazaroEdinburg$150K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.